874 — Guangzhou Baiyunshan Pharmaceutical Holdings Co Balance Sheet
0.000.00%
HealthcareBalancedMicro Cap
Annual balance sheet for Guangzhou Baiyunshan Pharmaceutical Holdings Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 17,819 | 21,013 | 22,979 | 20,557 | 20,752 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 17,015 | 19,175 | 20,652 | 21,526 | 21,512 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 47,397 | 52,811 | 57,064 | 55,984 | 57,762 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,260 | 5,836 | 6,570 | 7,516 | 7,939 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 59,760 | 66,118 | 74,665 | 78,587 | 81,684 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 29,243 | 32,254 | 37,395 | 36,235 | 38,916 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 33,615 | 37,056 | 42,600 | 43,668 | 45,779 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 26,145 | 29,062 | 32,065 | 34,919 | 35,905 |
Total Liabilities & Shareholders' Equity | 59,760 | 66,118 | 74,665 | 78,587 | 81,684 |
Total Common Shares Outstanding |